Top

Published in:

Open Access 01-07-2018 | Immunotherapy and Immunomodulators (B Vickery, Section Editor)

Next-Generation of Allergen-Specific Immunotherapies: Molecular Approaches

Authors: Mirela Curin, Musa Khaitov, Alexander Karaulov, Leyla Namazova-Baranova, Raffaela Campana, Victoria Garib, Rudolf Valenta

Published in: Current Allergy and Asthma Reports | Issue 7/2018

Abstract

Purpose of Review

The aim of this article is to discuss how allergen-specific immunotherapy (AIT) can be improved through molecular approaches. We provide a summary of next-generation molecular AIT approaches and of their clinical evaluation. Furthermore, we discuss the potential of next generation molecular AIT forms for the treatment of severe manifestations of allergy and mention possible future molecular strategies for the secondary and primary prevention of allergy.

Recent Findings

AIT has important advantages over symptomatic forms of allergy treatment but its further development is limited by the quality of the therapeutic antigen preparations which are derived from natural allergen sources. The field of allergy diagnosis is currently undergoing a dramatic improvement through the use of molecular testing with defined, mainly recombinant allergens which allows high-resolution diagnosis. Several studies demonstrate that molecular testing in early childhood can predict the development of symptomatic allergy later on in life.

Summary

Clinical studies indicate that molecular AIT approaches have the potential to improve therapy of allergic diseases and may be used as allergen-specific forms of secondary and eventually primary prevention for allergy.

Valenta R, Ferreira F, Focke-Tejkl M, Linhart B, Niederberger V, Swoboda I, et al. From allergen genes to allergy vaccines. Annu Rev Immunol. 2010;28:211–41. https://doi.org/10.1146/annurev-immunol-030409-101218.PubMedCrossRef

Anto JM, Bousquet J, Akdis M, Auffray C, Keil T, Momas I, et al. Mechanisms of the development of allergy (MeDALL): introducing novel concepts in allergy phenotypes. J Allergy Clin Immunol. 2017;139(2):388–99. https://doi.org/10.1016/j.jaci.2016.12.940.PubMedCrossRef

Bernstein DI, Schwartz G, Bernstein JA. Allergic rhinitis: mechanisms and treatment. Immunol Allergy Clin N Am. 2016;36(2):261–78. https://doi.org/10.1016/j.iac.2015.12.004.CrossRef

•• Valenta R, Karaulov A, Niederberger V, Gattinger P, van Hage M, Flicker S, et al. Molecular aspects of allergens and allergy. Adv Immunol. 2018;138:195–256. https://doi.org/10.1016/bs.ai.2018.03.002. Extremely comprehensive recent review informing what has been learned about mechanisms of allergy through molecular allergology.

Hatzler L, Panetta V, Lau S, Wagner P, Bergmann RL, Illi S, et al. Molecular spreading and predictive value of preclinical IgE response to Phleum pratense in children with hay fever. J Allergy Clin Immunol. 2012;130(4):894–901. https://doi.org/10.1016/j.jaci.2012.05.053.PubMedCrossRef

Custovic A, Sonntag HJ, Buchan IE, Belgrave D, Simpson A, Prosperi MCF, et al. Evolution pathways of IgE responses to grass and mite allergens throughout childhood. J Allergy Clin Immunol. 2015;136(6):1645–52. https://doi.org/10.1016/j.jaci.2015.03.041.PubMedCrossRef

•• Westman M, Lupinek C, Bousquet J, Andersson N, Pahr S, Baar A, et al. Early childhood IgE reactivity to pathogenesis-related class 10 proteins predicts allergic rhinitis in adolescence. J Allergy Clin Immunol. 2015;135(5):1199–206. https://doi.org/10.1016/j.jaci.2014.10.042. First study to demonstrate that molecular allergy testing early in childhood can predict the development of allergy later on for birch pollen and related allergies. PubMedCrossRef

Asarnoj A, Hamsten C, Lupinek C, Melén E, Andersson N, Anto JM, et al. Prediction of peanut allergy in adolescence by early childhood storage protein-specific IgE signatures: the BAMSE population-based birth cohort. J Allergy Clin Immunol. 2017;140(2):587–90. https://doi.org/10.1016/j.jaci.2016.12.973.PubMedCrossRef

Asarnoj A, Hamsten C, Wadén K, Lupinek C, Andersson N, Kull I, et al. Sensitization to cat and dog allergen molecules in childhood and prediction of symptoms of cat and dog allergy in adolescence: a BAMSE/MeDALL study. J Allergy Clin Immunol. 2016;137(3):813–21. https://doi.org/10.1016/j.jaci.2015.09.052.PubMedCrossRef

10.

Westman M, Asarnoj A, Hamsten C, Wickman M, van Hage M. Windows of opportunity for tolerance induction for allergy by studying the evolution of allergic sensitization in birth cohorts. Semin Immunol. 2017;30:61–6. https://doi.org/10.1016/j.smim.2017.07.005.PubMedCrossRef

11.

• Posa D, Perna S, Resch Y, Lupinek C, Panetta V, Hofmaier S, et al. Evolution and predictive value of IgE responses toward a comprehensive panel of house dust mite allergens during the first 2 decades of life. J Allergy Clin Immunol. 2017;139(2):541–9. https://doi.org/10.1016/j.jaci.2016.08.014. Analysis of the development of IgE sensitization to a comprehensive panel of house dust mite allergen molecules from birth to adolescence in a birth cohort. PubMedCrossRef

12.

•• Wickman M, Lupinek C, Andersson N, Belgrave D, Asarnoj A, Benet M, et al. Detection of IgE reactivity to a handful of allergen molecules in early childhood predicts respiratory allergy in adolescence. EBioMedicine. 2017;26:91–9. https://doi.org/10.1016/j.ebiom.2017.11.009. Study demonstrating in two birth cohorts from different countries that the development of respiratory allergy can be predicted by molecular allergy testing early in childhood with micro-arrayed allergen molecules. PubMedPubMedCentralCrossRef

13.

Möller C, Dreborg S, Ferdousi HA, Halken S, Høst A, Jacobsen L, et al. Pollen immunotherapy reduces the development of asthma in children with seasonal rhinoconjunctivitis (the PAT-study). J Allergy Clin Immunol. 2002;109(2):251–6. https://doi.org/10.1067/mai.2002.121317.PubMedCrossRef

14.

Jacobsen L, Niggemann B, Dreborg S, Ferdousi HA, Halken S, Høst A, et al. Specific immunotherapy has long-term preventive effect of seasonal and perennial asthma: 10-year follow-up on the PAT study. Allergy. 2007;62(8):943–8. https://doi.org/10.1111/j.1398-9995.2007.01451.x.PubMedCrossRef

15.

Valenta R, Campana R, Marth K, van Hage M. Allergen-specific immunotherapy: from therapeutic vaccines to prophylactic approaches. J Intern Med. 2012;272(2):144–57. https://doi.org/10.1111/j.1365-2796.2012.02556.PubMedPubMedCentralCrossRef

16.

Matricardi PM. Allergen-specific immunoprophylaxis: toward secondary prevention of allergic rhinitis? Pediatr Allergy Immunol. 2014;25(1):15–8. https://doi.org/10.1111/pai.12200.PubMedCrossRef

17.

Jutel M, Agache I, Bonini S, Burks AW, Calderon M, Canonica W, et al. International consensus on allergy immunotherapy. J Allergy Clin Immunol. 2015;136(3):556–68. https://doi.org/10.1016/j.jaci.2015.04.047.PubMedCrossRef

18.

• Valenta R, Campana R, Focke-Tejkl M, Niederberger V. Vaccine development for allergen-specific immunotherapy based on recombinant allergens and synthetic allergen peptides: lessons from the past and novel mechanisms of action for the future. J Allergy Clin Immunol. 2016;137(2):351–7. https://doi.org/10.1016/j.jaci.2015.12.1299. Useful review explaining molecular strategies for allergen-specific immunotherapy. PubMedPubMedCentralCrossRef

19.

Dhami S, Kakourou A, Asamoah F, Agache I, Lau S, Jutel M, et al. Allergen immunotherapy for allergic asthma: a systematic review and meta-analysis. Allergy. 2017;72(12):1825–48. https://doi.org/10.1111/all.13208.PubMedCrossRef

20.

Tam HH, Calderon MA, Manikam L, Nankervis H, Núñez IG, Williams HC, et al. Specific allergen immunotherapy for the treatment of atopic eczema: a Cochrane systematic review. Allergy. 2016;71(9):1345–56. https://doi.org/10.1111/all.12932.PubMedCrossRef

21.

Larché M, Akdis CA, Valenta R. Immunological mechanisms of allergen-specific immunotherapy. Nat Rev Immunol. 2006;6(10):761–71. https://doi.org/10.1038/nri1934.PubMedCrossRef

22.

Valenta R, Ball T, Focke M, Linhart B, Mothes N, Niederberger V, et al. Immunotherapy of allergic disease. Adv Immunol. 2004;82:105–53. https://doi.org/10.1016/S0065-2776(04)82003-0.PubMedCrossRef

23.

Burton OT, Logsdon SL, Zhou JS, Medina-Tamayo J, Abdel-Gadir A, Noval Rivas M, et al. Oral immunotherapy induces IgG antibodies that act through FcγRIIb to suppress IgE-mediated hypersensitivity. J Allergy Clin Immunol. 2014;134(6):1310–1317.e6. https://doi.org/10.1016/j.jaci.2014.05.042.PubMedPubMedCentralCrossRef

24.

Ejrnaes AM, Svenson M, Lund G, Larsen JN, Jacobi H. Inhibition of rBet v 1-induced basophil histamine release with specific immunotherapy -induced serum immunoglobulin G: no evidence that FcgammaRIIB signalling is important. Clin Exp Allergy. 2006;36(3):273–82. https://doi.org/10.1111/j.1365-2222.2006.02442.x.PubMedCrossRef

25.

van Neerven RJ, Wikborg T, Lund G, Jacobsen B, Brinch-Nielsen A, Arnved J, et al. Blocking antibodies induced by specific allergy vaccination prevent the activation of CD4+ T cells by inhibiting serum-IgE-facilitated allergen presentation. J Immunol. 1999;163(5):2944–52.PubMed

26.

•• Zieglmayer P, Focke-Tejkl M, Schmutz R, Lemell P, Zieglmayer R, Weber M, et al. Mechanisms, safety and efficacy of a B cell epitope-based vaccine for immunotherapy of grass pollen allergy. EBioMedicine. 2016;11:43–57. https://doi.org/10.1016/j.ebiom.2016.08.022. First clinical immunotherapy study describing safety and mechanisms of allergen-specific immunotherapy with a recombinant B cell epitope-based allergy vaccine. PubMedPubMedCentralCrossRef

27.

Mothes N, Heinzkill M, Drachenberg KJ, Sperr WR, Krauth MT, Majlesi Y, et al. Allergen-specific immunotherapy with a monophosphoryl lipid A-adjuvanted vaccine: reduced seasonally boosted immunoglobulin E production and inhibition of basophil histamine release by therapy-induced blocking antibodies. Clin Exp Allergy. 2003;33(9):1198–20. https://doi.org/10.1046/j.1365-2222.2003.01699.x.PubMedCrossRef

28.

Niederberger V, Horak F, Vrtala S, Spitzauer S, Krauth MT, Valent P, et al. Vaccination with genetically engineered allergens prevents progression of allergic disease. Proc Natl Acad Sci U S A. 2004;101(Suppl 2):14677–82. https://doi.org/10.1073/pnas.0404735101.PubMedPubMedCentralCrossRef

29.

Creticos PS, Schroeder JT, Hamilton RG, Balcer-Whaley SL, Khattignavong AP, Lindblad R, et al. Immunotherapy with a ragweed-toll-like receptor 9 agonist vaccine for allergic rhinitis. N Engl J Med. 2006;355(14):1445–55. https://doi.org/10.1056/NEJMoa052916.PubMedCrossRef

30.

•• Niederberger V, Neubauer A, Gevaert P, Zidarn M, Worm M, Aberer W, et al. Safety and efficacy of immunotherapy with the recombinant B-cell epitope-based grass pollen vaccine BM32. J Allergy Clin Immunol. 2018:31884–5. https://doi.org/10.1016/j.jaci.2017.09.052. Demonstration that AIT with the recombinant B cell epitope-based grass pollen allergy vaccine BM32 reduces symptoms of allergic rhinitis in a double-blind, placebo-controlled multicenter field study.

31.

Durham SR, Walker SM, Varga EM, Jacobson MR, O'Brien F, Noble W, et al. Long-term clinical efficacy of grass-pollen immunotherapy. N Engl J Med. 1999;341(7):468–75. https://doi.org/10.1056/NEJM199908123410702.PubMedCrossRef

32.

James LK, Shamji MH, Walker SM, Wilson DR, Wachholz PA, Francis JN, et al. Long-term tolerance after allergen immunotherapy is accompanied by selective persistence of blocking antibodies. J Allergy Clin Immunol. 2011;127(2):509–516.e1–5. https://doi.org/10.1016/j.jaci.2010.12.1080.PubMedCrossRef

33.

Dunbar WP. Zur Ursache und spezifischen Heilung des Heufiebers. Dtsch Med Wochenschr. 1903;9:24–8.

34.

Noon L. Prophylactic inoculation against hay fever. Lancet. 1911;1:1572–3.CrossRef

35.

Cooke RA, Barnard JH, Hebald S, Stull A. Serological evidence of immunity with coexisting sensitization in a type of human allergy (hay fever). J Exp Med. 1935;62(6):733–50.PubMedPubMedCentralCrossRef

36.

Sledge RF. Treatment of hay-fever with alum-precipitated pollen. US Naval Med Bull. 1938;36:18.

37.

Loveless MH. Immunological studies of pollinosis.I. The presence of two antibodies related to the same pollen antigen in the serum of treated hay fever patients. J Immunol. 1940;38:25–50.

38.

Frankland AW, Augustin R. Prophylaxis of summer hay-fever and asthma: a controlled trial comparing crude grass-pollen extracts with the isolated main protein component. Lancet. 1954;266:1055–7.PubMedCrossRef

39.

Marsh DG, Lichtenstein LM, Campbell DH. Studies on "allergoids" prepared from naturally occurring allergens. I. Assay of allergenicity and antigenicity of formalinized rye group I component. Immunology. 1970;18(5):705–22.PubMedPubMedCentral

40.

Rubinstein E, Fujita Y, Okazaki T, Tripodi D, Reisman RE, Arbesman CE. Effect of ragweed hyperimmune human gamma globulin on in vivo and in vitro parameters of ragweed sensitivity. J Allergy Clin Immunol. 1976;57(4):335–41.PubMedCrossRef

41.

Lee WY, Sehon AH. Abrogation of reaginic antibodies with modified allergens. Nature. 1977;267(5612):618–9.PubMedCrossRef

42.

Norman PS, Lichtenstein LM, Marsh DG. Studies on allergoids from naturally occurring allergens. IV. Efficacy and safety of long-term allergoid treatment of ragweed hay fever. J Allergy Clin Immunol. 1981;68(6):460–70.PubMedCrossRef

43.

Ball T, Vrtala S, Sperr WR, Valent P, Susani M, Kraft D, et al. Isolation of an immunodominant IgE hapten from an epitope expression cDNA library. Dissection of the allergic effector reaction. J Biol Chem. 1994;269(45):28323–8.PubMed

44.

Ferreira F, Hirtenlehner K, Jilek A, Godnik-Cvar J, Breiteneder H, Grimm R, et al. Dissection of immunoglobulin E and T lymphocyte reactivity of isoforms of the major birch pollen allergen Bet v 1: potential use of hypoallergenic isoforms for immunotherapy. J Exp Med. 1996;183(2):599–609. https://doi.org/10.1084/jem.183.2.599.PubMedCrossRef

45.

Vrtala S, Hirtenlehner K, Vangelista L, Pastore A, Eichler HG, Sperr WR, et al. Conversion of the major birch pollen allergen, Bet v 1, into two nonanaphylactic T cell epitope-containing fragments: candidates for a novel form of specific immunotherapy. J Clin Invest. 1997;99(7):1673–81. https://doi.org/10.1172/JCI119330.PubMedPubMedCentralCrossRef

46.

Raz E, Tighe H, Sato Y, Corr M, Dudler JA, Roman M, et al. Preferential induction of a Th1 immune response and inhibition of specific IgE antibody formation by plasmid DNA immunization. Proc Natl Acad Sci U S A. 1996;93(10):5141–5.PubMedPubMedCentralCrossRef

47.

Hsu CH, Chua KY, Tao MH, Lai YL, Wu HD, Huang SK, et al. Immunoprophylaxis of allergen-induced immunoglobulin E synthesis and airway hyperresponsiveness in vivo by genetic immunization. Nat Med. 1996;2(5):540–4.PubMedCrossRef

48.

Norman PS, Ohman JL Jr, Long AA, Creticos PS, Gefter MA, Shaked Z, et al. Treatment of cat allergy with T-cell reactive peptides. Am J Respir Crit Care Med. 1996;154:1623–8.PubMedCrossRef

49.

Simons FE, Imada M, Li Y, Watson WT, HayGlass KT. Fel d 1 peptides: effect on skin tests and cytokine synthesis in cat-allergic human subjects. Int Immunol. 1996;8(12):1937–45. https://doi.org/10.1016/S0140-6736(02)09332-7.PubMedCrossRef

50.

Jutel M, Jaeger L, Suck R, Meyer H, Fiebig H, Cromwell O. Allergen-specific immunotherapy with recombinant grass pollen allergens. J Allergy Clin Immunol. 2005;116:608–13. https://doi.org/10.1016/j.jaci.2005.06.004.PubMedCrossRef

51.

Pauli G, Larsen TH, Rak S, Horak F, Pastorello E, Valenta R, et al. Efficacy of recombinant birch pollen vaccine for the treatment of birch-allergic rhinoconjunctivitis. J Allergy Clin Immunol. 2008;122(5):951–60. https://doi.org/10.1016/j.jaci.2008.09.017.PubMedCrossRef

52.

Senti G, Prinz Vavricka BM, Erdmann I, Diaz MI, Markus R, McCormack SJ, et al. Intralymphatic allergen administration renders specific immunotherapy faster and safer: a randomized controlled trial. Proc Natl Acad Sci U S A. 2008;105(46):17908–12.PubMedPubMedCentralCrossRef

53.

Senti G, Crameri R, Kuster D, Johansen P, Martinez-Gomez JM, Graf N, et al. Intralymphatic immunotherapy for cat allergy induces tolerance after only 3 injections. J Allergy Clin Immunol. 2012;129(5):1290–6. https://doi.org/10.1016/j.jaci.2012.02.026.PubMedCrossRef

54.

• Su Y, Romeu-Bonilla E, Anagnostou A, Fitz-Patrick D, Hearl W, Heiland T. Safety and long-term immunological effects of CryJ2-LAMP plasmid vaccine in Japanese red cedar atopic subjects: a phase I study. Hum Vaccin Immunother. 2017;13(12):2804–13. https://doi.org/10.1080/21645515.2017.1329070. First clinical AIT study with a plasmid DNA vaccine. PubMedPubMedCentralCrossRef

55.

•• Orengo JM, Radin AR, Kamat V, Badithe A, Ben LH, Bennett BL, et al. Treating cat allergy with monoclonal IgG antibodies that bind allergen and prevent IgE engagement. Nat Commun. 2018;9(1):1421. https://doi.org/10.1038/s41467-018-03636-8. First demonstration that passive immunization with recombinant human allergen-specific IgG antibodies specific for the cat allergen Fel d 1 is effective for the treatment of cat allergy. PubMedPubMedCentralCrossRef

56.

Durham SR, Schwabe C, Robson R, Ahlström Emanuelsson C, Shamji M, Singh D, et al. A randomized clinical trial of passive immunotherapy with single-dose anti-Fel d 1 monoclonal antibodies REGN 1908–1909 in cat induced rhinoconjunctivitis: exploratory efficacy endpoints, safety. Allergy. 2017;72(Suppl. S103):64–5.

57.

Lessof MH, Sobotka AK, Lichtenstein LM. Effects of passive antibody in bee venom anaphylaxis. Johns Hopkins Med J. 1978;142(1):1–7.PubMed

58.

Bousquet J, Fontez A, Aznar R, Robinet-Levy M, Michel FB. Combination of passive and active immunization in honeybee venom immunotherapy. J Allergy Clin Immunol. 1987;79(6):947–54.PubMedCrossRef

59.

Sadovnichaya LT, Nemykina OE, Sadovnichaya TA. Efficacy of human antiallergic immunoglobulin in the treatment of ambrosia pollinosis in children. Medical Immunology (Russia). 1999;1(3–4):131–2.

60.

Giusan AO, Karpov VP. Complex histaglobin and allergoid therapy of seasonal allergic diseases of the upper respiratory tract. Vestn Otorinolaringol. 1983;2:68–69.

61.

Sidelnikov VM, Pashun TV, Pomytkina LR. Comparative evaluation of the effectiveness of different methods of prophylactic treatment for children with bronchial asthma. Pediatriia 1985;4:34–36.

62.

Paci A, Taddeucci-Brunelli G, Barachini P, Magliaccio P, Pierini G, Crimaldi G. Pediatr Med Chir 1986;8:839–844.

63.

Flicker S, Steinberger P, Norderhaug L, Sperr WR, Majlesi Y, Valent P, et al. Conversion of grass pollen allergen-specific human IgE into a protective IgG(1) antibody. Eur J Immunol. 2002;32(8):2156–62. https://doi.org/10.1002/1521-4141(200208)32:8<2156::AID-IMMU2156>3.0.CO;2-A.PubMedCrossRef

64.

Flicker S, Valenta R. Renaissance of the blocking antibody concept in type I allergy. Int Arch Allergy Immunol. 2003;132(1):13–24. https://doi.org/10.1159/000073260.PubMedCrossRef

65.

Winther L, Arnved J, Malling HJ, Nolte H, Mosbech H. Side-effects of allergen-specific immunotherapy: a prospective multi-Centre study. Clin Exp Allergy. 2006;36(3):254–60.PubMedCrossRef

66.

Epstein TG, Liss GM, Murphy-Berendts K, Bernstein DI. Risk factors for fatal and nonfatal reactions to subcutaneous immunotherapy: national surveillance study on allergen immunotherapy (2008–2013). Ann Allergy Asthma Immunol. 2016;116(4):354–359.e2. https://doi.org/10.1016/j.anai.2016.02.001.PubMedCrossRef

67.

Briner TJ, Kuo MC, Keating KM, Rogers BL, Greenstein JL. Peripheral T-cell tolerance induced in naive and primed mice by subcutaneous injection of peptides from the major cat allergen Fel d I. Proc Natl Acad Sci U S A. 1993;90(16):7608–12.PubMedPubMedCentralCrossRef

68.

Vrtala S, Hirtenlehner K, Susani M, Akdis M, Kussebi F, Akdis CA, et al. Genetic engineering of a hypoallergenic trimer of the major birch pollen allergen Bet v 1. FASEB J. 2001;15(11):2045–7. https://doi.org/10.1096/fj.00-0767fje.PubMedCrossRef

69.

Valenta R. The future of antigen-specific immunotherapy of allergy. Nat Rev Immunol. 2002;2(6):446–53. https://doi.org/10.1038/nri824.PubMedCrossRef

70.

• Valenta R, Campana R, Niederberger V. Recombinant allergy vaccines based on allergen-derived B cell epitopes. Immunol Lett. 2017;189:19–26. https://doi.org/10.1016/j.imlet.2017.04.015. Review describing the mechanisms underlying recombinant B cell epitope-based allergy vaccines and their potential advantages. PubMedCrossRef

71.

Slater JE, Paupore E, Zhang YT, Colberg-Poley AM. The latex allergen Hev b 5 transcript is widely distributed after subcutaneous injection in BALB/c mice of its DNA vaccine. J Allergy Clin Immunol. 1998;102(3):469–75.PubMedCrossRef

72.

Valenta R, Linhart B, Swoboda I, Niederberger V. Recombinant allergens for allergen-specific immunotherapy: 10 years anniversary of immunotherapy with recombinant allergens. Allergy. 2011;66(6):775–83. https://doi.org/10.1111/j.1398-9995.2011.02565.x.PubMedCrossRef

73.

Wallner BP, Gefter ML. Immunotherapy with T-cell-reactive peptides derived from allergens. Allergy. 1994;49(5):302–8.PubMedCrossRef

74.

Morgenstern JP, Griffith IJ, Brauer AW, Rogers BL, Bond JF, Chapman MD, et al. Amino acid sequence of Fel dI, the major allergen of the domestic cat: protein sequence analysis and cDNA cloning. Proc Natl Acad Sci U S A. 1991;88(21):9690–4.PubMedPubMedCentralCrossRef

75.

Haselden BM, Kay AB, Larché M. Immunoglobulin E-independent major histocompatibility complex-restricted T cell peptide epitope-induced late asthmatic reactions. J Exp Med. 1999;189:1885–94. https://doi.org/10.1084/jem.189.12.1885.PubMedPubMedCentralCrossRef

76.

Maguire P, Nicodemus C, Robinson D, Aaronson D, Umetsu DT. The safety and efficacy of ALLERVAX CAT in cat allergic patients. Clin Immunol. 1999;93:222–31. https://doi.org/10.1006/clim.1999.4795.PubMedCrossRef

77.

Worm M, Lee HH, Kleine-Tebbe J, Hafner RP, Laidler P, Healey D, et al. Development and preliminary clinical evaluation of a peptide immunotherapy vaccine for cat allergy. J Allergy Clin Immunol. 2011;127(1):89–97. https://doi.org/10.1016/j.jaci.2010.11.029. 97.e1–14PubMedCrossRef

78.

Patel D, Couroux P, Hickey P, Salapatek AM, Laidler P, Larché M, et al. Fel d 1-derived peptide antigen desensitization shows a persistent treatment effect 1 year after the start of dosing: a randomized, placebo-controlled study. J Allergy Clin Immunol. 2013;131:103–9. https://doi.org/10.1016/j.jaci.2012.07.028.PubMedCrossRef

79.

Linhart B, Valenta R. Mechanisms underlying allergy vaccination with recombinant hypoallergenic allergen derivatives. Vaccine. 2012;30(29):4328–35. https://doi.org/10.1016/j.vaccine.2011.11.011.PubMedCrossRef

80.

Saarne T, Kaiser L, Grönlund H, Rasool O, Gafvelin G, van Hage-Hamsten M. Rational design of hypoallergens applied to the major cat allergen Fel d 1. Clin Exp Allergy. 2005;35(5):657–63.PubMedCrossRef

81.

Zuidmeer-Jongejan L, Huber H, Swoboda I, Rigby N, Versteeg SA, Jensen BM, et al. Development of a hypoallergenic recombinant parvalbumin for first-in-man subcutaneous immunotherapy of fish allergy. Int Arch Allergy Immunol. 2015;166(1):41–51. https://doi.org/10.1159/000371657. PubMedCrossRef

82.

Curin M, Weber M, Thalhamer T, Swoboda I, Focke-Tejkl M, Blatt K, et al. Hypoallergenic derivatives of Fel d 1 obtained by rational reassembly for allergy vaccination and tolerance induction. Clin Exp Allergy. 2014;44(6):882–94. https://doi.org/10.1111/cea.12294.PubMedPubMedCentralCrossRef

83.

Chen KW, Blatt K, Thomas WR, Swoboda I, Valent P, Valenta R, et al. Hypoallergenic Der p 1/Der p 2 combination vaccines for immunotherapy of house dust mite allergy. J Allergy Clin Immunol. 2012;130(2):435–43.e4. https://doi.org/10.1016/j.jaci.2012.05.035.PubMedPubMedCentralCrossRef

84.

Linhart B, Mothes-Luksch N, Vrtala S, Kneidinger M, Valent P, Valenta RA. Hypoallergenic hybrid molecule with increased immunogenicity consisting of derivatives of the major grass pollen allergens, Phl p 2 and Phl p 6. Biol Chem. 2008;389(7):925–33. https://doi.org/10.1515/BC.2008.105. PubMedCrossRef

85.

Schmitz N, Dietmeier K, Bauer M, Maudrich M, Utzinger S, Muntwiler S, et al. Displaying Fel d1 on virus-like particles prevents reactogenicity despite greatly enhanced immunogenicity: a novel therapy for cat allergy. J Exp Med. 2009;206(9):1941–55. https://doi.org/10.1084/jem.20090199.PubMedPubMedCentralCrossRef

86.

Spertini F, DellaCorte G, Kettner A, de Blay F, Jacobsen L, Jutel M, et al. Efficacy of 2 months of allergen-specific immunotherapy with Bet v 1-derived contiguous overlapping peptides in patients with allergic rhinoconjunctivitis: results of a phase 2b study. J Allergy Clin Immunol. 2016;138:162–8. https://doi.org/10.1016/j.jaci.2016.02.044.PubMedCrossRef

87.

Spertini F, Perrin Y, Audran R, Pellaton C, Boudousquié C, Barbier N, et al. Safety and immunogenicity of immunotherapy with Bet v 1-derived contiguous overlapping peptides. J Allergy Clin Immunol. 2014;134(1):239–40. https://doi.org/10.1016/j.jaci.2014.04.001.PubMedCrossRef

88.

Purohit A, Niederberger V, Kronqvist M, Horak F, Grönneberg R, Suck R, et al. Clinical effects of immunotherapy with genetically modified recombinant birch pollen Bet v 1 derivatives. Clin Exp Allergy. 2008;38(9):1514–25. https://doi.org/10.1111/j.1365-2222.2008.03042.x.PubMedCrossRef

89.

Kahlert H, Suck R, Weber B, Nandy A, Wald M, Keller W, et al. Characterization of a hypoallergenic recombinant Bet v 1 variant as a candidate for allergen-specific immunotherapy. Int Arch Allergy Immunol. 2008;145(3):193–206. https://doi.org/10.1159/000109288.PubMedCrossRef

90.

Klimek L, Bachert C, Lukat KF, Pfaar O, Meyer H, Narkus A. Allergy immunotherapy with a hypoallergenic recombinant birch pollen allergen rBet v 1-FV in a randomized controlled trial. Clin Transl Allergy. 2015;5:28. https://doi.org/10.1186/s13601-015-0071-x. eCollection 201.

91.

Weiss R, Scheiblhofer S, Thalhamer J. Generation and evaluation of prophylactic mRNA vaccines against allergy. Methods Mol Biol. 2017;1499:123–39. https://doi.org/10.1007/978-1-4939-6481-9_7.PubMedCrossRef

92.

Roesler E, Weiss R, Weinberger EE, Fruehwirth A, Stoecklinger A, Mostböck S, et al. Immunize and disappear-safety-optimized mRNA vaccination with a panel of 29 allergens. J Allergy Clin Immunol. 2009;124(5):1070–7.e1-11. https://doi.org/10.1016/j.jaci.2009.06.036.PubMedCrossRef

93.

Roy K, Mao HQ, Huang SK, Leong KW. Oral gene delivery with chitosan—DNA nanoparticles generates immunologic protection in a murine model of peanut allergy. Nat Med. 1999;5(4):387–91. https://doi.org/10.1038/7385.PubMedCrossRef

94.

Tighe H, Takabayashi K, Schwartz D, Van Nest G, Tuck S, Eiden JJ, et al. Conjugation of immunostimulatory DNA to the short ragweed allergen Amb a 1 enhances its immunogenicity and reduces its allergenicity. J Allergy Clin Immunol. 2000;106(1 Pt 1):124–34. https://doi.org/10.1067/mai.2000.107927. PubMedCrossRef

95.

Senti G, Johansen P, Haug S, Bull C, Gottschaller C, Müller P, et al. Use of A-type CpG oligodeoxynucleotides as an adjuvant in allergen-specific immunotherapy in humans: a phase I/IIa clinical trial. Clin Exp Allergy. 2009;39(4):562–70. https://doi.org/10.1111/j.1365-2222.2008.03191.x.PubMedCrossRef

96.

Chapman MD, Ferreira F, Villalba M, Cromwell O, Bryan D, Becker WM, et al. The European Union CREATE project: a model for international standardization of allergy diagnostics and vaccines. J Allergy Clin Immunol. 2008;122(5):882–889.e2. https://doi.org/10.1016/j.jaci.2008.07.030.PubMedCrossRef

97.

Himly M, Nony E, Chabre H, Van Overtvelt L, Neubauer A, van Ree R, et al. Standardization of allergen products: 1. Detailed characterization of GMP-produced recombinant Bet v 1.0101 as biological reference preparation. Allergy. 2009;64(7):1038–45. https://doi.org/10.1111/j.1398-9995.2009.01957.x.PubMedCrossRef

98.

Vieths S, Barber D, Chapman M, Costanzo A, Daas A, Fiebig H, et al. Establishment of recombinant major allergens Bet v 1 and Phl p 5a as Ph. Eur. reference standards and validation of ELISA methods for their measurement. Results from feasibility studies. Pharmeur Bio Sci Notes. 2012;2012:118–34.PubMed

99.

Nony E, Bouley J, Le Mignon M, Lemoine P, Jain K, Horiot S, et al. Development and evaluation of a sublingual tablet based on recombinant Bet v 1 in birch pollen-allergic patients. Allergy. 2015;70:795–804. https://doi.org/10.1111/all.12622.PubMedCrossRef

100.

Valenta R, Vrtala S, Focke-Tejkl M, Bugajska-Schretter BT, Twardosz A, et al. Genetically engineered and synthetic allergen derivatives: candidates for vaccination against type I allergy. Biol Chem. 1999;380(7-8):815–24. https://doi.org/10.1515/BC.1999.101.PubMedCrossRef

101.

Focke M, Swoboda I, Marth K, Valenta R. Developments in allergen-specific immunotherapy: from allergen extracts to allergy vaccines bypassing allergen-specific immunoglobulin E and T cell reactivity. Clin Exp Allergy. 2010;40(3):385–97. https://doi.org/10.1111/j.1365-2222.2009.03443.x.PubMedCrossRef

102.

Campana R, Mothes N, Rauter I, Vrtala S, Reininger R, Focke-Tejkl M, et al. Non-IgE-mediated chronic allergic skin inflammation revealed with rBet v 1 fragments. J Allergy Clin Immunol. 2008;121(2):528–530.e1. https://doi.org/10.1016/j.jaci.2007.09.014.PubMedCrossRef

103.

Focke M, Mahler V, Ball T, Sperr WR, Majlesi Y, Valent P, et al. Nonanaphylactic synthetic peptides derived from B cell epitopes of the major grass pollen allergen, Phl p 1, for allergy vaccination. FASEB J. 2001 Sep;15(11):2042–4.PubMedCrossRef

104.

Focke M, Linhart B, Hartl A, Wiedermann U, Sperr WR, Valent P, et al. Non-anaphylactic surface-exposed peptides of the major birch pollen allergen, Bet v 1, for preventive vaccination. Clin Exp Allergy. 2004;34(10):1525–33.PubMedCrossRef

105.

Twaroch TE, Focke M, Civaj V, Weber M, Balic N, Mari A, et al. Carrier-bound, nonallergenic Ole e 1 peptides for vaccination against olive pollen allergy. J Allergy Clin Immunol. 2011;128(1):178–184.e7. https://doi.org/10.1016/j.jaci.2011.03.011.PubMedCrossRef

106.

Chen KW, Focke-Tejkl M, Blatt K, Kneidinger M, Gieras A, Dall'Antonia F, et al. Carrier-bound nonallergenic Der p 2 peptides induce IgG antibodies blocking allergen-induced basophil activation in allergic patients. Allergy. 2012;67(5):609–21. https://doi.org/10.1111/j.1398-9995.2012.02794.x.PubMedPubMedCentralCrossRef

107.

Niespodziana K, Focke-Tejkl M, Linhart B, Civaj V, Blatt K, Valent P, et al. A hypoallergenic cat vaccine based on Fel d 1-derived peptides fused to hepatitis B PreS. J Allergy Clin Immunol. 2011;127(6):1562–70.e6. https://doi.org/10.1016/j.jaci.2011.02.004.PubMedCrossRef

108.

Marth K, Breyer I, Focke-Tejkl M, Blatt K, Shamji MH, Layhadi J, et al. A nonallergenic birch pollen allergy vaccine consisting of hepatitis PreS-fused Bet v 1 peptides focuses blocking IgG toward IgE epitopes and shifts immune responses to a tolerogenic and Th1 phenotype. J Immunol. 2013;190(7):3068–78. https://doi.org/10.4049/jimmunol.1202441.PubMedPubMedCentralCrossRef

109.

Banerjee S, Weber M, Blatt K, Swoboda I, Focke-Tejkl M, Valent P, et al. Conversion of Der p 23, a new major house dust mite allergen, into a hypoallergenic vaccine. J Immunol. 2014;192(10):4867–75. https://doi.org/10.4049/jimmunol.1400064.PubMedPubMedCentralCrossRef

110.

• Focke-Tejkl M, Weber M, Niespodziana K, Neubauer A, Huber H, Henning R, et al. Development and characterization of a recombinant, hypoallergenic, peptide-based vaccine for grass pollen allergy. J Allergy Clin Immunol. 2015;135(5):1207–7.e1-11. https://doi.org/10.1016/j.jaci.2014.09.012. Description of the preclinical and immunological characterization of a novel type of recombinant B cell epitope-based allergy vaccine for grass pollen allergy. PubMedPubMedCentralCrossRef

111.

Niederberger V, Marth K, Eckl-Dorna J, Focke-Tejkl M, Weber M, Hemmer W, et al. Skin test evaluation of a novel peptide carrier-based vaccine, BM32, in grass pollen-allergic patients. J Allergy Clin Immunol. 2015;136(4):1101–3.e8. https://doi.org/10.1016/j.jaci.2015.03.034.PubMedCrossRef

112.

• Weber M, Niespodziana K, Linhart B, Neubauer A, Huber H, Henning R, et al. Comparison of the immunogenicity of BM32, a recombinant hypoallergenic B cell epitope-based grass pollen allergy vaccine with allergen extract-based vaccines. J Allergy Clin Immunol. 2017;140(5):1433–1436.e6. https://doi.org/10.1016/j.jaci.2017.03.048. Comparison of the immunogenicity of the recombinant B cell epitope-based grass pollen allergy vaccine BM32 with allergen extract-based vaccines used for treatment. PubMedCrossRef

113.

•• Cornelius C, Schöneweis K, Georgi F, Weber M, Niederberger V, Zieglmayer P, et al. Immunotherapy with the PreS-based grass pollen allergy vaccine BM32 induces antibody responses protecting against hepatitis B infection. EBioMedicine. 2016;11:58–67. https://doi.org/10.1016/j.ebiom.2016.07.023. Demonstration that PreS-specific IgG antibodies induced in patients with the recombinant B cell epitope-based grass pollen allergy vaccine BM32 protect in vitro against infection with hepatitis B virus. PubMedPubMedCentralCrossRef

114.

Gerlich WH, Glebe D. Development of an allergy immunotherapy leads to a new type of hepatitis B vaccine. EBioMedicine. 2016;11:5–6. https://doi.org/10.1016/j.ebiom.2016.07.032.PubMedPubMedCentralCrossRef

115.

Linhart B, Narayanan M, Focke-Tejkl M, Wrba F, Vrtala S, Valenta R. Prophylactic and therapeutic vaccination with carrier-bound Bet v 1 peptides lacking allergen-specific T cell epitopes reduces Bet v 1-specific T cell responses via blocking antibodies in a murine model for birch pollen allergy. Clin Exp Allergy. 2014;44(2):278–87. https://doi.org/10.1111/cea.12216.PubMedPubMedCentralCrossRef

116.

• Campana R, Huang HJ, Freidl R, Linhart B, Vrtala S, Wekerle T, et al. Recombinant allergen and peptide-based approaches for allergy prevention by oral tolerance. Semin Immunol. 2017;30:67–80. https://doi.org/10.1016/j.smim.2017.08.017. An outlook to the potential of primary allergy prevention by oral tolerance induction with recombinant allergens and allergen peptides. PubMedCrossRef

117.

Baranyi U, Linhart B, Pilat N, Gattringer M, Bagley J, Muehlbacher F, et al. Tolerization of a type I allergic immune response through transplantation of genetically modified hematopoietic stem cells. J Immunol. 2008;180(12):8168–75. Cell-based therapy in allergyPubMedPubMedCentralCrossRef

118.

• Baranyi U, Farkas AM, Hock K, Mahr B, Linhart B, Gattringer M, et al. Cell therapy for prophylactic tolerance in immunoglobulin E-mediated allergy. EBioMedicine. 2016;7:230–9. https://doi.org/10.1016/j.ebiom.2016.03.028. Demonstration that cell therapy can prevent the development of allergy in a murine model. PubMedPubMedCentralCrossRef

119.

Baranyi U, Gattringer M, Valenta R, Wekerle T. Cell-based therapy in allergy. Curr Top Microbiol Immunol. 2011;352:161–79. https://doi.org/10.1007/82_2011_127.PubMedCrossRef

Title: Next-Generation of Allergen-Specific Immunotherapies: Molecular Approaches
Authors: Mirela Curin
Musa Khaitov
Alexander Karaulov
Leyla Namazova-Baranova
Raffaela Campana
Victoria Garib
Rudolf Valenta
Publication date: 01-07-2018
Publisher: Springer US
Published in: Current Allergy and Asthma Reports / Issue 7/2018
Print ISSN: 1529-7322
Electronic ISSN: 1534-6315
DOI: https://doi.org/10.1007/s11882-018-0790-x

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Next-Generation of Allergen-Specific Immunotherapies: Molecular Approaches

Abstract

Purpose of Review

Recent Findings

Summary

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose of Review

Recent Findings

Summary

Please log in to get access to this content